Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 16/20 | 0.59 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.59 |
| ▸ | MMP3 | P08254 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503697 | 0.90 | ADAM17 (0.61) | ADAM17ADAM10MMP3HTTLMNA | |
| SCHEMBL1503699 | 0.90 | ADAM17 (0.61) | ADAM17ADAM10MMP3HTTLMNA | |
| SCHEMBL12076911 | 0.89 | ADAM17 (0.76) | ADAM17ADAM10MMP3MMP1 | |
| SCHEMBL1503542 | 0.89 | ADAM17 (0.76) | ADAM17ADAM10MMP3MMP1 | |
| SCHEMBL1503641 | 0.86 | ADAM17 (0.79) | ADAM17ADAM10MMP3HTTLMNA | |
| SCHEMBL1503628 | 0.82 | ADAM17 (0.80) | ADAM17ADAM10MMP3HTTLMNA | |
| SCHEMBL1503625 | 0.82 | ADAM17 (0.80) | ADAM17ADAM10MMP3HTTLMNA | |
| SCHEMBL1503590 | 0.80 | ADAM17 (0.82) | ADAM17ADAM10MMP3HTTMMP1 | |
| SCHEMBL12077178 | 0.80 | ADAM17 (0.82) | ADAM17ADAM10MMP3HTTMMP1 | |
| SCHEMBL1503633 | 0.80 | ADAM17 (0.52) | ADAM17ADAM10MMP3LMNAMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011033010-A1 | 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-03-24 | — | — | WO | disclosed |